U.S. market Closed. Opens in 1 day 1 hour 9 minutes

PNT | POINT Biopharma Global Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for PNT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is strong.

Valuation (9%)

Company Industry
P/E Ratio (TTM) -26.34 -15.27
PEG Ratio (TTM) -9.40 -4.35
P/S Ratio (TTM) 174.00 45.97
P/B Ratio (TTM) 3.12 28.96
P/FCF Ratio (TTM) -11.46 -2.59
Price to 5YR AVG Earnings Ratio N/A -5.56
Price to 5YR AVG FCF Ratio N/A -12.33

Profitability (0%)

Company Industry
ROA (TTM) -10.51% -19.06%
ROE (TTM) -11.52% 15.70%
Net Profit Margin (TTM) -655.51% -813.88%
ROIC 5YR AVG N/A 3.12%

Growth (42%)

4QTR AVG 3YR AVG 5YR AVG
EPS 152.58% 61.80% N/A
Revenue -46.76% N/A N/A
Net Income 154.64% -12,024.75% N/A
Cash Flow 220.44% 24.07% N/A

Health (70%)

Company Industry
Current Ratio (TTM) 9.14 5.56
Quick Ratio (TTM) 9.03 5.34
D/E Ratio (TTM) 0.03 0.95
Interest Coverage (TTM) N/A -6.44
Piotroski F-Score 5 5
Altman Z-Score 17.03 12.45
LTL to 5YR AVG FCF N/A 0.11
Shares Outstanding Growth 5YR AVG N/A 37.46%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙